ClinicalTrials.gg

Program

Gemfibrozil

Also written as “PLX-200”, “Gemfibrozil Tablets” and “gemfibrozil”.

Its studies are mostly in Neuronal Ceroid-Lipofuscinoses · Parkinson Disease · Lysosomal Storage Diseases · Anemia · Diabetes Mellitus, Type 2, led by 7 companies.

Furthest: phase 3, since Nov 4, 20208 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Polaryx Therapeutics21 open or runningphase 3since Nov 4, 2020Nov 4, 2020Dec 31, 2028phase 2 · NCT07740512
Blu Caribe10 open or runningphase 1since Nov 26, 2008Nov 26, 2008none ahead
Eli Lilly10 open or runningphase 1since Nov 26, 2012Nov 26, 2012none ahead
Elixir Pharmaceuticals10 open or runningphase 1since Dec 3, 2007Dec 3, 2007none ahead
Forest Hills Lab10 open or runningphase 2since Jun 15, 2023Jun 15, 2023none ahead
GlaxoSmithKline10 open or runningphase 1since Jun 16, 2011Jun 16, 2011none ahead
Johnson & Johnson10 open or runningphase 1since May 11, 2016May 11, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2007First study: phase 1 study in Diabetes Mellitus, Type 2New to Elixir PharmaceuticalsElixir Pharmaceuticals · NCT00566865 · 14 enrolled
  2. Nov 26, 2008Blu Caribe's first study: phase 1 study in BioavailabilityNew to Blu CaribeBlu Caribe · NCT00800475 · 40 enrolled
  3. Jun 16, 2011GlaxoSmithKline's first study: phase 1 study in AnemiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT01376232 · 23 enrolled · India
  4. Nov 26, 2012Eli Lilly's first study: phase 1 study in Healthy VolunteersNew to Eli LillyEli Lilly · NCT01736254 · 24 enrolled · United States
  5. May 11, 2016Johnson & Johnson's first study: phase 1 study in Healthy SubjectsNew to Johnson & JohnsonJohnson & Johnson · NCT02770222 · 40 enrolled
  6. Nov 4, 2020Polaryx Therapeutics's first study: phase 3 study in Neuronal Ceroid-LipofuscinosesNew to Polaryx TherapeuticsPolaryx Therapeutics · NCT04637282
  7. Jun 15, 2023Forest Hills Lab's first study: phase 2 study in Parkinson DiseaseNew to Forest Hills LabForest Hills Lab · NCT05931484
  8. Jul 17, 2026Phase 2 study in Lysosomal Storage DiseasesPolaryx Therapeutics · NCT07740512 · 24 planned

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Lysosomal Storage DiseasesPolaryx Therapeutics · NCT07740512

TargetBeta

PPARA →read by rule
“Peroxisome proliferator-activated receptor alpha agonist”ChEMBL 37, by rule

Other programs on PPARA

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
pemafibrateruleKowaphase 417
elifibranorruleGenfitphase 324
seladelparruleGilead Sciencesphase 314
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07740512Lysosomal Storage Diseases2Not yet recruitingPolaryx TherapeuticsDec 31, 202824
NCT05931484Parkinson Disease2WithdrawnForest Hills LabNov 1, 20280
NCT04637282Neuronal Ceroid-Lipofuscinoses3WithdrawnPolaryx TherapeuticsDec 31, 20260
NCT02770222Healthy Subjects1CompletedJohnson & JohnsonJul 201640
NCT01736254Healthy Volunteers · United States1CompletedEli LillyFeb 201324
NCT01376232Anemia · India1CompletedGlaxoSmithKlineDec 20, 201023
NCT00800475Bioavailability1CompletedBlu CaribeJul 200540
NCT00566865Diabetes Mellitus, Type 21CompletedElixir PharmaceuticalsDec 200714

How it is read

Names in the registry

  • “Gemfibrozil”, 4 entries
  • “PLX-200”, 2 entries
  • “Gemfibrozil Tablets”, 1 entry
  • “gemfibrozil”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.